Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adriano Lazzarin

Showing results (231-240 of 288) with videos related to

Pageof 29
Sort By:
Medicine and Science in Sports and Exercise|August 16, 2019
A Mobile Application for Exercise Intervention in People Living with HIVMatteo Bonato, Filippo Turrini, Valentina DE Zan, et al.
The Journal of Antimicrobial Chemotherapy|March 7, 2016
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trialLaura Galli, Vincenzo Spagnuolo, Alba Bigoloni, et al.
AIDS (London, England)|February 13, 2024
Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapyChloe Orkin, Andrea Antinori, Jürgen K Rockstroh, et al.
Pharmacogenetics and Genomics|January 11, 2011
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphismMarco Siccardi, Antonio D'Avolio, Silvia Nozza, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2006
Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage studyNicola Gianotti, Vincenzo Mondino, Maria Cristina Rossi, et al.
The Journal of Antimicrobial Chemotherapy|January 23, 2015
Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patientsElisa Rita Ceresola, Silvia Nozza, Michela Sampaolo, et al.
The Journal of Infectious Diseases|December 11, 2012
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING StudyJoseph J Eron, Bonaventura Clotet, Jacques Durant, et al.
The New England Journal of Medicine|May 30, 2003
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and AustraliaAdriano Lazzarin, Bonaventura Clotet, David Cooper, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 11, 2010
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT studyHans-Jürgen Stellbrink, Chloe Orkin, Jose Ramon Arribas, et al.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)|December 3, 2004
Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trialsPedro E Cahn, José M Gatell, Kathleen Squires, et al.
Pageof 29

Showing results (231-240 of 288) with videos related to

Sort By:
Pageof 29
Medicine and Science in Sports and Exercise|August 16, 2019
A Mobile Application for Exercise Intervention in People Living with HIVMatteo Bonato, Filippo Turrini, Valentina DE Zan, et al.
The Journal of Antimicrobial Chemotherapy|March 7, 2016
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trialLaura Galli, Vincenzo Spagnuolo, Alba Bigoloni, et al.
AIDS (London, England)|February 13, 2024
Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapyChloe Orkin, Andrea Antinori, Jürgen K Rockstroh, et al.
Pharmacogenetics and Genomics|January 11, 2011
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphismMarco Siccardi, Antonio D'Avolio, Silvia Nozza, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 19, 2006
Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage studyNicola Gianotti, Vincenzo Mondino, Maria Cristina Rossi, et al.
The Journal of Antimicrobial Chemotherapy|January 23, 2015
Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patientsElisa Rita Ceresola, Silvia Nozza, Michela Sampaolo, et al.
The Journal of Infectious Diseases|December 11, 2012
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING StudyJoseph J Eron, Bonaventura Clotet, Jacques Durant, et al.
The New England Journal of Medicine|May 30, 2003
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and AustraliaAdriano Lazzarin, Bonaventura Clotet, David Cooper, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 11, 2010
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT studyHans-Jürgen Stellbrink, Chloe Orkin, Jose Ramon Arribas, et al.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)|December 3, 2004
Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trialsPedro E Cahn, José M Gatell, Kathleen Squires, et al.
Pageof 29